PHILADELPHIA, PA, Ceptur Therapeutics, a biotechnology company, announced the completion of a $75M Series A financing co-led by venBio Partners and Qiming Venture Partners.
Ceptur Therapeutics, a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75M Series A financing.
The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors along with existing Seed investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
